{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.2","upperLimit":"47.0","value":"37.3"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"4.9","value":"0.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"48 Weeks","title":"The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48","type":"SECONDARY","unitOfMeasure":"percentage of participants"}